As on (01 Mar 2024 | 00:51)
Back To Homepage As on (01 Mar 2024 | 00:51)
Sun Pharma enters into license agreement with Pharmazz Back
(14 Sep 2023)
Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries has entered into a license agreement with Pharmazz Inc., (Pharmazz), a U.S. based biopharmaceutical company to commercialise a first-in-class innovative drug, Tyvalzi™(Sovateltide) in India. Developed by Pharmazz for potential global use, Sovateltide is indicated for treating cerebral ischemic stroke.

As per agreement terms, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi™ (Sovateltide). Pharmazz will be entitled to upfront and milestone payments,including royalties.